Sarcoma  >>  Votrient (pazopanib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Votrient (pazopanib) / Novartis, BeiGene
NCT01130623: A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Withdrawn
1
0
US
Pazopanib (GW786034)
National Cancer Institute (NCI)
Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
11/11
11/11
NCT01012362: Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Checkmark Data-AACR
Mar 2012 - Mar 2012: Data-AACR
Terminated
1
31
US
Pazopanib, Pazopanib hydrochloride, GW786034B, Ixabepilone, IXEMPRA(TM)
Masonic Cancer Center, University of Minnesota, GlaxoSmithKline
Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer, Head and Neck Cancer, Kidney Cancer, Sarcoma, Hepatocellular Cancer
02/13
02/13
NCT00929903 / 2012-001306-20: Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Completed
1
55
US
pazopanib hydrochloride, GW786034B, Votrient, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Metastatic Childhood Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway Glioma, Unspecified Childhood Solid Tumor, Protocol Specific
04/13
 
PASART-1, NCT01985295: Combined Modality Treatment of Sarcomas of the Extremities

Completed
1
12
Europe
pazopanib, Compound Number: GW786034
The Netherlands Cancer Institute, GlaxoSmithKline
Sarcoma,Soft Tissue
08/14
11/14
NCT01438554: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark AACR-NCI-EORTC 2013
Oct 2013 - Oct 2013: AACR-NCI-EORTC 2013
Checkmark P1 data-ASCO
More
Completed
1
89
US
Pazopanib, Votrient, GSK1120212, Trametinib, Mekinist
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Comprehensive Cancer Network, Novartis
Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
04/16
08/18
NCT02795819: Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Terminated
1
6
US
AR-42, HDAC-42, OSU-HDAC42, Pazopanib, Votrient
Virginia Commonwealth University, National Cancer Institute (NCI)
Renal Cell Carcinoma, Soft Tissue Sarcoma, Metastatic Disease
11/16
03/19
NCT03275558: Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Withdrawn
1
0
RoW
Axitinib 1 MG, AG 013736, Inlyta, Sunitinib 5 MG, SU11248, Sutent, Pazopanib 5 MG, GW786034, Votrient
Center Trials & Treatment
Recurrent Glioblastoma, Gliosarcoma, Anaplastic Gliomas
07/18
07/18
NCT03139331: PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Completed
1
16
US
Pazopanib, Irinotecan, Temozolomide
University of California, San Francisco, UCSF Benioff Children's Hospital Oakland, Dana-Farber Cancer Institute, Alex's Lemonade Stand Foundation
Sarcoma, Refractory Sarcoma
10/19
09/20
NCT01543763: Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
More
Active, not recruiting
1
90
US
PZP115891, PCI-24781, abexinostat, S 78454, GW786034, Votrient™, Pazopanib
Pamela Munster, Pharmacyclics LLC., Novartis, Xynomic Pharmaceuticals, Inc., GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
Metastatic Solid Tumors
01/24
12/24
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Not yet recruiting
1
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25

Download Options